ABSTRACT
Four categories of patients with advanced gastric cancer treated with different regimens of chemotherapy: (1) PF cisplatin 100 mg/m2/day+5-fluorouracil 1000 mg/m2/day intravenous infusion (100 hrs); (2) carboplatin (AUC5)+5-fluorouracil 500 mg/m2/day intravenous infusion (2 hrs), days 1-3; (3) DCF, and (4) bevacizumab+PF.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Stomach Neoplasms/drug therapy , Antibodies, Monoclonal/administration & dosage , Antibodies, Monoclonal, Humanized , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Bevacizumab , Cancer Care Facilities , Carboplatin/administration & dosage , Cisplatin/administration & dosage , Docetaxel , Drug Administration Schedule , Fluorouracil/administration & dosage , Humans , Infusions, Intravenous , Russia , Stomach Neoplasms/pathology , Taxoids/administration & dosage , Treatment OutcomeABSTRACT
Complex examination of 32 patients with gastric cancer in terms of more than 6 months after radical operations included endoscopic, radial and laboratory methods with the determination of indices of the carcinoembryonic antigen and carbohydrate antigens 19-1 and 72-4 every six months. It was established that normal concentration of all the three tumor markers within 12 months after surgery was a practically reliable sign of the absence of metastases and recurrence of gastric cancer. The increased level of one or two oncomarkers within 12 months after radical operation points to progression of gastric cancer with probability of 57.1% or the development of other surgical pathology (cholecystolithiasis, gastric stump polyps and others) in 28.6% of observations. In all cases of progressing gastric cancer in terms of more than 6 months after operation there was a more that 1.5 times elevation of any one or two tumor markers.
Subject(s)
Biomarkers, Tumor/blood , Gastrectomy , Monitoring, Physiologic/methods , Postoperative Care/methods , Stomach Neoplasms/diagnosis , Disease Progression , Endoscopy, Gastrointestinal , Follow-Up Studies , Humans , Neoplasm Metastasis , Neoplasm Staging/methods , Positron-Emission Tomography , Prognosis , Stomach Neoplasms/blood , Stomach Neoplasms/secondary , Tomography, Spiral ComputedABSTRACT
Preoperative indices of cancer embryonic antigen (CEA), carbohydrate antigens 19-9(CA)19-9, 72-4(CA)72-4, and alfa-fetaprotein (AFP) in 60 patients with gastric cancer were compared with the results of postoperative staging of the malignant process. It was found that increased concentration of one of the tumor markers were not a significant diagnostic sign of the metastases of gastric cancer. CEA is considered as an exception since its more than one and a half elevation (more than 3.75 ng/ml) suggests the presence of metastases with 80% probability. An increased concentration of any two oncomarkers (CEA, CA19-9, CA 72-4) points to the metastases of gastric cancer with 83.3% probability and usually coincides with the presence of distant metastases. A simultaneous elevation of indices of three tumor markers does not occur in gastric cancer. AFP is not informative in cases of gastric cancer and its dissemination.
